ALK and non-small cell lung carcinoma: Overall, our meta-analysis suggests that the addition of immune checkpoint inhibitor to standard chemotherapy benefited OS and PFS, including tumors with EGFR and ALK alterations in first-line, advanced, metastatic NSCLC.